Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20210315833Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye Disorders
US 14.10.2021
Int.Class A61K 31/047
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
047having two or more hydroxy groups, e.g. sorbitol
Appl.No 17304708 Applicant ZeaVision LLC Inventor Dennis L. Gierhart

Oral formulations for promoting eye health, and in particular for preventing or treating macular degeneration, are disclosed, containing zeaxanthin, a carotenoid pigment, and at least two or more additional ocular-active nutrients selected from lipoic acid, omega-3 fatty acids, plant-derived compounds such as flavonoids, anthocyanins, or polyphenolics, taurine, carnitine, Coenzyme-Q10, carnosine, and nutrients that stimulate the production of glutathione. Processes are disclosed for identifying ocular-active nutrients that will interact in a synergistic and potentiating manner with zeaxanthin, to provide better and more effective protection, for eye health, than can be provided by zeaxanthin alone. Additional optional agents include zinc, vitamin E, and vitamin C.

2.20210315843ENDOXIFEN FOR THE TREATMENT OF BIPOLAR I DISORDER
US 14.10.2021
Int.Class A61K 31/138
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
Appl.No 17226628 Applicant Jina Pharmaceuticals, Inc. Inventor Ateeq AHMAD

A method for maintaining a therapeutically effective concentration of endoxifen for the treatment of patient with bipolar I disorder is provided. The method includes administering to the patient a dose of 2 mg to 16 mg of endoxifen citrate in an enteric coated tablet once per day for at least 21 days. Further, the said method provides a desirable in-vivo plasma profile. The therapeutic dose monitoring is not required in a patient undergoing the said treatment. Furthermore, the method provides a significant improvement in mania assessed by the YMRS and the MADRS scores in patient undergoing the said treatment. Furthermore, the method as provides an early response time of the treatment in at least 2 days and remission time that is not more than 4 days in patient undergoing the said treatment.

3.20210315935TREATMENT OF VON WILLEBRAND DISEASE
US 14.10.2021
Int.Class A61K 35/19
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
19Platelets; Megacaryocytes
Appl.No 17166490 Applicant Cellphire, Inc. Inventor Keith Andrew Moskowitz

Provided herein are methods and compositions for treating von Willebrand disease with platelets, platelet derivatives, and/or thrombosomes.

4.20210316016VECTOR FOR GENE SILENCING AND REPLACEMENT AND METHODS OF USE THEREOF
US 14.10.2021
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No 17346639 Applicant WISCONSIN ALUMNI RESEARCH FOUNDATION Inventor MATTHEW MICHAEL MILLETTE

An expression cassette for gene silencing and replacement, including, in operable communication, a promoter, an expression attenuator, a nucleotide sequence encoding a gene for a replacement target protein, and an shRNA sequence for knockdown of an endogenous variant of the target protein, wherein the promoter, the expression attenuator, the nucleotide sequence encoding the gene for the replacement target protein, and the shRNA are expressed as a single transcript. Also included are expression vectors and cells. Also included are methods of silencing and replacement of a target gene in a cell in culture by transforming the cells with the expression vectors described herein. Also included are minimal expression cassettes suitable for therapeutic methods.

5.20210315838SYSTEMS, METHODS, AND KITS FOR DIAGNOSTICS AND TREATMENT OF VIRAL RESPIRATORY INFECTION
US 14.10.2021
Int.Class A61K 31/05
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
Appl.No 17301188 Applicant Applied Biology, Inc. Inventor Ofer A. Goren

The present disclosure includes methods, systems, kits and compositions for treating, preventing and diagnosing viral infections, specifically SARS-CoV-2 infections, with an anti-androgen and anti-thyroid medication, a thyroid receptor antagonist, a TGF-β inhibitor or a combination thereof. The present disclosure also describes methods and compositions for the treatment of viral respiratory diseases, specifically SARS-CoV-2 infections, including anti-androgens, anti-thyroid medications, thyroid receptor antagonists, TGF-β inhibitors, RXR inhibitors, furin inhibitors or other agents to disrupt the androgen signaling.

6.20210315845ENDOXIFEN FOR THE TREATMENT OF BIPOLAR I DISORDER
US 14.10.2021
Int.Class A61K 31/138
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines, e.g. amantadine
135having aromatic rings, e.g. methadone
138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
Appl.No 17226671 Applicant Jina Pharmaceuticals, Inc. Inventor Ateeq AHMAD

A method for maintaining a therapeutically effective concentration of endoxifen for treatment of a patient with bipolar I disorder is provided. The said method includes administering to the patient, a dose of 2 mg to 16 mg of endoxifen citrate in an enteric coated tablet once per day for at least 21 days. Further, the patient is not required to be administered rescue medication during the administration of the endoxifen citrate.

7.20210315906Botanical Extracts and Compounds from Schinus Plants and Methods of Use
US 14.10.2021
Int.Class A61K 31/569
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
565not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
568substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
569substituted in position 17 alpha, e.g. ethisterone
Appl.No 17357353 Applicant Emory University Inventor Cassandra L. Quave

This disclosure relates to extracts from the Anacardiaceae (cashew plant family) and compositions comprising compounds contained therein. In certain embodiments, the extracts are derived from the fruit of a Schinus plant. In certain embodiments, the disclosure relates to methods of treating or preventing bacterial infections, acne, and other related uses.

8.20210317116N-1 BRANCHED CYCLOALKYL SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS
US 14.10.2021
Int.Class C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Appl.No 17250073 Applicant 3M INNOVATIVE PROPERTIES COMPANY Inventor George W. GRIESGRABER

Imidazo[4,5-c]quinoline compounds of Formula (I) having a substituent that is attached at the N−1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

embedded image

9.20210317170COMPOSITIONS AND METHODS FOR DRUG DELIVERY AND TREATING VIRAL INFECTIONS
US 14.10.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17086957 Applicant UT-Battelle, LLC Inventor Joseph Christopher Ellis

The present disclosure is directed to compositions and methods for targeted drug delivery that comprise a biocompatible framework carrying at least one drug and a viral surface protein, where the viral surface protein mediates entry into a target cell and is attached to an outer surface of the biocompatible framework in the drug carrier.

10.WO/2021/203168TREATMENT FOR SEPSIS-INDUCED ORGAN DYSFUNCTION
WO 14.10.2021
Int.Class A61K 31/375
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
375Ascorbic acid, i.e. vitamin C; Salts thereof
Appl.No PCT/AU2021/050321 Applicant THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH Inventor BELLOMO, Rinaldo
Provided herein are methods for treating or preventing a condition, and/or symptom or clinical manifestation, associated with systemic infection wherein a subject is intravenously administered ascorbic acid or a pharmaceutically acceptable salt, ester or isomer thereof in an amount of between about 700 mg/kg body weight and about 4,000 mg/kg body weight per day, optionally as a first bolus infusion followed by a subsequent continuous infusion. Also provided are methods comprising intravenously administering to the subject ascorbic acid or a pharmaceutically acceptable salt, ester or isomer thereof: (i) as a bolus dose of from about 350 mg/kg body weight to about 500 mg/kg body weight; and (ii) following (i), by continuous infusion over at least several hours at a dose of from about 60 mg/kg body weight/hr to about 500 mg/kg body weight/hr. Typically, the condition is sepsis or septic shock.